Anthony J. Gringeri, Ph.D.

Chief Executive Officer

Dr. Gringeri is a seasoned biopharma executive with a record of significant accomplishments in both scientific and commercial matters as well as broad international managerial experience. Dr. Gringeri has a PhD in Pharmacology at the University of Rochester and has worked in the biopharmaceutical industry for over 30 years in positions of increasing responsibility. At Boehringer Ingelheim Pharmaceuticals, he managed several clinical trials and contributed to the Atrovent NDA. Later, at Amgen, Dr. Gringeri led the team that successfully developed a medical device, the Miltenyi CliniMACS, as part of a joint venture (AmCell) with the German firm, Miltenyi Biotec. He also was a member of the management committee that oversaw AmCell. Subsequently, he led the international team that developed Aranesp, a second-generation erythropoietic protein, in North America, Europe and Australia. He led the Aranesp program for five years through commercial launch for both nephrology and oncology indications. As Vice President, Renal Diseases and Anemia, he was responsible for overseeing Epogen, Amgen’s flagship commercial product, and Sensipar, Amgen’s first small molecule. Later experience included Chief of Staff to the EVP of Research and Development, Vice President of Project Management and Strategic Planning, and Vice President of Scientific Outreach and Licensing Operations. Through most of his Amgen years, Dr. Gringeri also worked closely with Investor Relations, acting as liaison between R&D and Wall Street.

From 2006 to 2010, Dr. Gringeri was Chief Operating Officer at Amsterdam Molecular Therapeutics (now UniQure), a European gene therapy company; his responsibilities included overseeing business development and clinical operations, building the pipeline, guiding regulatory interactions, and working jointly with the CEO to develop and execute a corporate strategic plan, including taking the company public. Dr. Gringeri supervised the completion of the clinical program and submission of the MAA that led to European registration of Glybera (first approved gene therapy worldwide). In 2011-2012, he was Vice President and Chief Development Officer at ViaCyte, a company pursuing cellular therapy of Type I diabetes. From 2013 to 2016, Dr. Gringeri was Senior Vice President at ImmunoCellular Therapeutics, where he oversaw all clinical development, regulatory, and manufacturing activity. He was CEO of ImmunoCellular from 2016 to 2018, overseeing all aspects of corporate activity and successfully raising $13 million.